Everything's Special At US FDA: Priority NDA/BLA Filings Surge

The FY 2018 PDUFA performance report also indicates that applications with standard assessments fell compared to long-term averages.

FDA entrance sign 2016
The FY 2018 PDUFA Performance Report also detailed falling median approval times. • Source: File photo

Standard assessment periods may be losing favor with sponsors of new drugs and biologics, creating more stress for the US Food and Drug Administration staff.

Priority application filings, which promise an eight-month review rather than the standard 12-month review, showed a dramatic increase in fiscal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

Senate Panel Approves US CDC Director Candidate Monarez With Measles Outbreak Growing

 
• By 

The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.

US FDA Advisory Committee Supports Vaccine Safety, Scrutinizes AE Reporting Quality

 
• By 

The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.